Cargando…
Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells
BACKGROUND: Mutations in one allele of the TP53 gene in early stages are frequently followed by the loss of the remaining wild-type p53 (wtp53) allele (p53LOH) during tumor progression. Despite the strong notion of p53LOH as a critical step in tumor progression, its oncogenic outcomes that facilitat...
Autores principales: | Ghaleb, Amr, Padellan, Malik, Marchenko, Natalia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709447/ https://www.ncbi.nlm.nih.gov/pubmed/33267874 http://dx.doi.org/10.1186/s13058-020-01370-y |
Ejemplares similares
-
Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53
por: Ghaleb, Amr, et al.
Publicado: (2019) -
p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
por: Alexandrova, Evguenia M, et al.
Publicado: (2017) -
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity
por: Isermann, Tamara, et al.
Publicado: (2021) -
NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022) -
Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas
por: Goto, Akiteru, et al.
Publicado: (1998)